Neoplasms

Symptoms and General Pathology

All Conditions

Neoplastic Cells, Circulating

Antineoplastic Agents

All Drugs and Chemicals

Herbal and Botanical

Fulvestrant

Immunomodulating Agents

Palbociclib

Chrysanthemum

Monitoring of patients with tumours treated by immune therapy.

Timing of blood sampling:

* inclusion
* after #8 weeks on therapy
* at progression or 6 months from inclusion for patient without progressive disease
* if toxicity grade 3 or 4, or grade 2 until 1 month.

Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).

Timing of blood sampling:

* inclusion
* after 1 cycle of therapy (weeks 3-4)
* up to 2 other samples, timepoints decided by the investigator

Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).

One tumor sampling.

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.

One tumor sampling.

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Monitoring of patients treated with palbociclib

Timing of blood sampling:

* Inclusion day (2 samples)
* after #2 weeks of therapy
* after #4 weeks of therapy
* at progression.

Detection of PD-L1 in metastatic breast cancer patients

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Detection of PD-L1 in metastatic lung cancer patients

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.

Blood sampling at 4 timepoints.

Monitoring of patient with a metastatic breast cancer treated by palbociclib.

Timing of blood sampling:

* Inclusion
* after #4 weeks of therapy
* at the first tumoral evaluation (month 3 or 4)
* at progression.

The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.

Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.

Timing of blood sampling:

* Inclusion
* after #3-5 weeks of therapy
* at the first tumoral evaluation (month 2 or 3)
* at progression.

The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).

Timing of blood sampling:

* J1C1
* J2C1
* J1C2
* J1C5 (first tumoral evaluation).

This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.

One tumour sampling.

Timing of blood sampling:

* before treatment
* at W8 of treatment (after radiological examination)
* at W12 of treatment
* at progression or 18 months after the beginning of treatment

This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.

Timing of blood sampling:

* At inclusion
* After biopsy post inclusion (or in 15 days after)
* after 1 or 2 months of treatment
* at progression or 18 months after inclusion

This cohort concerns patients with metastatic uveal melanoma before immunotherapy treatment.

Timing of blood sampling :

* at inclusion
* at cycle 2 or 3 of treatment
* at the first tumoral evaluation (C5D1)
* at progression

Up to 5 blood samplings can be performed at different time points

Blood sampling

One tumor sampling can be performed, if applicable

Tumor sampling

Stool sampling

François-Clément BIDARD, MD PhD

Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.

Exploratory multi-cohort study including different types of cancer (different organs and/or different histological types).

Each kind of blood-borne biological markers analyses corresponds to a cohort.

Analysis of Circulating Tumor Markers in the Blood (ALCINA)

Analysis of Circulating Tumor Markers in the Blood

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients ".

Number of biological analysis results correlated to clinical data. Establishment of a proof of concept

Institut Curie

Blood and Lymph Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Constiutional DNA sampling

Dominique Genre, MD

Jihane PAKRADOUNI, PharmD,PhD

Dominique GENRE, MD

Norbert VEY, MD

Adult acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy associated with poor prognosis, especially after relapse. High-throughput genomic studies have highlighted the importance of molecular alteration in the pathophysiology, clinical evolution and treatment response of AML. In addition, identification of specific gene mutation can be targeted by specific inhibitors, opening the way to personalized treatments. However, only a limited number of gene mutations are druggable or actionable, highlighting the need for additional information to guide treatment choices. Among them, new Drug Screening Tests (DST) allow for the screening of library of hundreds of drugs to ex-vivo patient-derived AML cells. Combination of genomic and pharmacologic approaches might therefore improve prediction of drug effects. There is an urgent need to bring these approaches into the clinic but feasibility trials are necessary before incorporating them into treatments strategies.The proposed study is a prospective multicentre feasibility study of a combined "chemo-genomic" approach in patients with advanced AML.

ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia

ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia- CeGAL-IPC 2014-012

Cancer Research Center of Marseille

Institut Paoli-Calmettes

Nervous System Diseases

Neoplasm Metastasis

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

The study population will comprise 200 (two hundred) adult patients candidate to neurosurgical treatment for newly diagnosed malignant brain tumors, able to express an informed consent.

Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype

Circulating leukocytes immunophenotype

Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.

Laura Sincinelli

Pietro Mortini, MD, Prof.

The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome.

Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.

High-grade gliomas are the most frequent type of primary brain tumor in adults, and among them, glioblastoma multiforme (GBM) is the most malignant with an associated poor prognosis. Although significant advances have been achieved in GBM biology comprehension, patients' life expectancy is still limited to 18 months.

Brain metastases (BM) are the most frequent neoplasm in the CNS; it is estimated that up to 14% of all newly diagnosed cancers will soon or later metastasize into the brain.

A variety of mechanisms to escape a tumor-specific T cell-mediated immune response have been identified in glioma and other cancer entities.

This project is an observational, prospective, monocentric study on patients candidates for neurosurgical procedures for brain malignant tumors with additional collection of biological material. With the present study, we aim to characterize the phenotype of both circulating- and tumor-infiltrating- immune cells at the diagnosis and their changes during disease progression and after treatment in primary and secondary brain tumors.

Samples will be taken at baseline (before surgery) and at time-points: 3, 6, 9, 12 months

Blood samples for lymphocyte extraction and immunophenotype detection.

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.

Leucocytes count (10\^3/ml), total lymphocytes count (10\^3/ml)

Determination of different leucocyte subpopulations (%)

Infiltrating lymphocytes count (10\^3/ml)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Analysis of Circulating Tumor Markers in the Blood (ALCINA)	NCT02866149	Cancer	Blood sampling Tumor sampling Stool sampling	18 Years -	Institut Curie
Analysis of Circulating Tumor Markers in the Blood (ALCINA)	NCT02866149	Cancer	Blood sampling Tumor sampling Stool sampling	18 Years -	Institut Curie
ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia	NCT02619071	Leukemia, Myelo...	Tumor sampling Constiutional D...	18 Years -	Institut Paoli-Calmettes
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors	NCT05831631	Brain Tumor, Pr... Brain Tumor - M...	Circulating leu... Tumor sampling	18 Years -	IRCCS San Raffaele

Spots Global Cancer Trial Database for tumor sampling